0001683168-26-003762
SEC filingPaySign delivered exceptional top-line growth and operating leverage in Q1 FY2026, with revenue up 50.8% and operating income surging 167.9% — driven by scaled execution across plasma and pharma patient affordability programs and a favorable shift toward higher-margin revenue streams.
Gross profit increased 55.8% to $18.2 million, and gross margin expanded to 65.0%. This improvement reflects a favorable revenue mix shift toward higher-margin programs, particularly within pharma patient affordability initiatives. However, the increase in gross profit was partially offset by higher costs — including network fees, third-party service providers, sales commission expense, and customer service costs — all driven by overall business growth. These cost increases are consistent with operational scaling and do not indicate margin erosion.
Operating income surged 167.9% to $6.7 million, and operating margin rose to 23.8%. This outsized growth in profitability relative to revenue signals strong operating leverage, as fixed-cost infrastructure — including the processing platform enhanced through software development and equipment purchases — absorbed rapid volume growth. Depreciation and amortization expense increased, primarily due to amortization of intangible assets from the Gamma acquisition and continued capitalization of new software development costs — investments that underpin long-term scalability.
Management confirmed that internally generated funds will support continued expansion into new vertical markets without requiring new capital. During the remainder of 2026, PaySign plans to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance — all aimed at sustaining scalable growth while maintaining platform integrity and compliance rigor.